Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program
03 févr. 2022 07h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC
13 janv. 2022 07h00 HE
|
Salarius Pharmaceuticals, Inc.
Transformative acquisition significantly expands Salarius’ oncology pipeline into the targeted degradation space with ability to go after undruggable cancer-promoting targets, a rapidly growing area...
Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
10 déc. 2021 08h10 HE
|
Arvinas Inc.
– ARV-471 continues to show a favorable tolerability profile and robust ER degradation in updated phase 1 dose escalation data presented at San Antonio Breast Cancer Symposium – – ARV-471 is...
Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium
19 nov. 2021 09h55 HE
|
Arvinas Inc.
NEW HAVEN, Conn. and NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose...
Arvinas to Present at Stifel 2021 Virtual Healthcare Conference
10 nov. 2021 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update
03 nov. 2021 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies
27 oct. 2021 07h00 HE
|
Nurix Therapeutics, Inc.
Robust BTK target degradation achieved in all patients treated to date Greater than 90% degradation of BTK was achieved at the 200 mg dose of NX-2127 These data represent the first proof of...
Nurix Therapeutics to Present Initial Target Degradation Data from First Phase 1 Trial of NX-2127 in B Cell Malignancies at the 4th Annual Targeted Protein Degradation Summit
26 oct. 2021 16h02 HE
|
Nurix Therapeutics, Inc.
Presentation to include initial pharmacokinetic and BTK degradation data Company to host conference call at 8:30 a.m. ET on Wednesday, October 27, 2021 SAN FRANCISCO, Oct. 26, 2021 (GLOBE...
Nurix Therapeutics to Participate in the 4th Annual Targeted Protein Degradation Summit
21 oct. 2021 07h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Nurix’s...
Arvinas to Participate in Upcoming Virtual Investor Conferences
01 sept. 2021 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...